Elements for Success in Managing Type 2 Diabetes With SGLT-2 Inhibitors: Overview of the Efficacy and Safety of SGLT-2 Inhibitors in Type 2 Diabetes Mellitus.

Since the approval of the first sodium-glucose cotransporter-2 (SGLT-2) inhibitor by the US Food and Drug Administration (FDA) in 2013, the SGLT-2 inhibitors have assumed key roles in the management of patients with type 2 diabetes mellitus (T2DM). This review covers the safety and efficacy of these agents when used in this patient population.